BioCardia (BCDA) CEO Peter Altman adds 5,000 shares in open-market buy

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,000 shares of common stock at $0.85 per share. After this transaction, he directly owns 298,266 BioCardia common shares, indicating a modest increase in his personal equity stake in the company.

Insider Trade Summary

Net Buyer: 5,000 shares ($4,250)

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,000 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$0.85	$4K

Holdings After Transaction: Common Stock — 298,266 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 5,000 shares Purchase price: $0.85 per share Shares owned after transaction: 298,266 shares

3 metrics

Shares purchased 5,000 shares Open-market buy of common stock

Purchase price $0.85 per share Price paid in the June 9, 2026 transaction

Shares owned after transaction 298,266 shares Direct holdings following the purchase

Key Terms

open-market purchase, transaction code P, Form 4

3 terms

open-market purchase financial

"reported an open-market purchase of 5,000 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

transaction code P regulatory

"Transaction code P on the BioCardia Form 4 indicates a purchase"

Form 4 regulatory

"What does transaction code P mean in the BioCardia (BCDA) Form 4?"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		P		5,000	A	$0.85	298,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David McClung, by power of attorney	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioCardia (BCDA) report for Peter Altman?

BioCardia reported that President and CEO Peter Altman purchased 5,000 shares of common stock in an open-market transaction. The shares were bought at a price of $0.85 per share, modestly increasing his direct ownership position in the company.

At what price did the BioCardia (BCDA) CEO buy new shares?

Peter Altman bought 5,000 BioCardia common shares at $0.85 per share in an open-market purchase. This disclosed transaction price helps investors understand the level at which the CEO recently added to his equity position.

How many BioCardia (BCDA) shares does the CEO own after this transaction?

Following the purchase, Peter Altman directly owns 298,266 shares of BioCardia common stock. This updated total reflects his increased personal investment and is disclosed to give investors better visibility into insider ownership levels.

Was the BioCardia (BCDA) CEO transaction a purchase or a sale?

The transaction was a purchase. Peter Altman executed an open-market buy of 5,000 BioCardia common shares, classified as a purchase under transaction code P, rather than selling or disposing of any existing holdings.

What does transaction code P mean in the BioCardia (BCDA) Form 4?

Transaction code P on the BioCardia Form 4 indicates a purchase in the open market or a private transaction. In this case, it confirms that Peter Altman acquired 5,000 additional common shares rather than selling or gifting stock.